These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18681777)

  • 1. Pharmacogenetics of etanercept in rheumatoid arthritis.
    Danila MI; Hughes LB; Bridges SL
    Pharmacogenomics; 2008 Aug; 9(8):1011-5. PubMed ID: 18681777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.
    Kooloos WM; de Jong DJ; Huizinga TW; Guchelaar HJ
    Drug Discov Today; 2007 Feb; 12(3-4):125-31. PubMed ID: 17275732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis.
    Coenen MJ; Toonen EJ; Scheffer H; Radstake TR; Barrera P; Franke B
    Pharmacogenomics; 2007 Jul; 8(7):761-73. PubMed ID: 17638513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept: therapeutic use in patients with rheumatoid arthritis.
    Garrison L; McDonnell ND
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I65-9. PubMed ID: 10577976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
    Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
    Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?
    Murdaca G; Gulli R; Spanò F; Mandich P; Puppo F
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S7-S10. PubMed ID: 25381983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of rheumatoid arthritis with etanercept.
    Genovese MC; Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept in the treatment of rheumatoid arthritis.
    Hunt L; Emery P
    Expert Opin Biol Ther; 2013 Oct; 13(10):1441-50. PubMed ID: 23991717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creutzfeldt-Jakob disease in a patient treated by etanercept for rheumatoid arthritis (RA): just a coincidence?
    Soubrier M; Haïk S; Hauw JJ; Corvol JC; Lyon-Caen O; Dougados M
    Joint Bone Spine; 2010 Mar; 77(2):174-5. PubMed ID: 20097590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein].
    Fujikawa K; Kawakami A; Eguchi K
    Nihon Rinsho; 2007 Jul; 65(7):1211-7. PubMed ID: 17642234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept: a new option in the management of RA.
    Lovell CM
    J Am Pharm Assoc (Wash); 1999; 39(3):412-4. PubMed ID: 10363471
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.
    Padyukov L; Lampa J; Heimbürger M; Ernestam S; Cederholm T; Lundkvist I; Andersson P; Hermansson Y; Harju A; Klareskog L; Bratt J
    Ann Rheum Dis; 2003 Jun; 62(6):526-9. PubMed ID: 12759288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association of TNF-alpha polymorphism (-308 A/G) with high activity of rheumatoid arthritis and therapy response to Etanercept].
    Stojanović S; Jevtović-Stoimenov T; Stanković A; Pavlović D; Neković J; Stamenković B; Dimić A; Marinković M
    Srp Arh Celok Lek; 2011; 139(11-12):784-9. PubMed ID: 22338476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of rheumatoid arthritis: etanercept a recent advance.
    Halin J
    J Am Acad Nurse Pract; 2000 Oct; 12(10):433-41; quiz 442-4. PubMed ID: 11930442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Etanercept].
    Takeuchi T; Amano K
    Nihon Rinsho; 2002 Dec; 60(12):2390-6. PubMed ID: 12510367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.
    Mikuls TR; Moreland LW
    Expert Opin Pharmacother; 2001 Jan; 2(1):75-84. PubMed ID: 11336570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept Immunex.
    Yung RL
    Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.